TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
TVRD

Tvardi Therapeutics, Inc.

Healthcare · Biotechnology

0.7928$ -8.1% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Tvardi Therapeutics, Inc. (TVRD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 72.2% of the shares are freely tradable; institutional investors hold 28.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 28.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 34.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 72.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 1.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 13Mio.

Largest Shareholders

Institutions

Institutions TVRD
Name Stake (%) Shares Change (%) Date
Slate Path Capital LP 5.28 704,118 +0.0 06/30/2026
Vanguard Capital Management, LLC 2.58 344,382 -0.1 06/30/2026
American Financial Group Inc 1.68 223,659 +0.0 06/30/2026
UBS Group AG 0.83 111,133 +120.3 06/30/2026
Silvercrest Asset Management Group LLC 0.76 101,034 +0.0 06/30/2026
BlackRock Inc 0.72 95,478 -75.4 06/30/2026
Renaissance Technologies Corp 0.69 91,409 -0.8 06/30/2026
Geode Capital Management, LLC 0.68 90,350 -50.4 06/30/2026
Morgan Stanley - Brokerage Accounts 0.58 77,845 +6.8 06/30/2026

Funds

Funds TVRD
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.94 258,426 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?